Lecture Notes

**Lecture Coverage:**
- Schizophrenia & Antipsychotics
- Parkinson's Disease & L-DOPA

---
#### **Schizophrenia & Antipsychotics**
- Treats positive symptoms of Schizophrenia (Hallucinations & Delusion)
	- ∵ Hyperactivity specifically in the <abbr Title="from midbrain to Nucleus Accumbens">Mesolimbic pathway</abbr> in charge of reward & addiction

**Mechanism of Action**
- D<sub>2</sub> Receptor Antagonism → ↓ <abbr Title="esp. Mesolimbic pathway">Central</abbr> Dopaminergic Transmission

**Types of Antipsychotics**

|             Type             |                Examples                | Mechanism                                                                         | Characteristics                               |
| :--------------------------: | :------------------------------------: | --------------------------------------------------------------------------------- | --------------------------------------------- |
| 1st Generation<br>(Typical)  |     Haloperidol<br>Chlorpromazine      | Strong D<sub>2</sub> Antagonism → Positive Symptom                                | ↑ EPS Risk<br>                                |
| 2nd Generation<br>(Atypical) | Olanzapine<br>Clozapine<br>Risperidone | Weaker D<sub>2</sub> Antagonism<br>5-HT<sub>2</sub> Antagonism → Negative Symptom | ↓ EPS Risk<br>↑ Lipid Metabolism Side Effects |

**Side Effects**
- Nigrostriatal Pathway Dopamine Blockade → <abbr Title="Extrapyramidal Symptoms">EPS</abbr>:
	- Acute Dystonia: Sudden Muscle Spasms
	- Tardive Dyskinesia: Abnormal Facial & Trunk Movements
	- Akathisia: Motor Restlessness
	- Pseudo-Parkinsonism: Tremor & Rigidity
- Tuberoinfundibular Pathway Dopamine Blockade
	- ↑ [[Lecture 3.1 (Endocrine System) - Endocrine Control & Actions|Prolactin]] Secretion
- ↓ Drug Specificity → Blockade of Other Receptors
	- α<sub>1</sub> Blockade: Postural Hypotension
	- H<sub>1</sub> Blockade: Sedation
	- M Blockade: Constipation & Urinary Retention


#### **Parkinson's Disease & L-DOPA**
- Parkinson's Disease: 
	- Progressive Dopaminergic Loss in Substantia Nigra → ↓ Nigrostriatal Pathway Dopamine Transmission → Motor symptoms
- L-DOPA:
	- Dopamine precursor that can pass BBB → Converted by <abbr Title="DOPA decarboxylase">DDC</abbr> in brain
	- Enhance remaining Dopamine transmission in Nigrostriatal Pathway

**L-DOPA Enhancing Drugs**
- Peripheral DDC Inhibitors (Carbidopa, Benserazide)
	- Inhibits <abbr Title="e.g. Gut, Liver">Peripheral</abbr> DDC
	- Side Effect: 
